- Presentation to Be Webcast Live on Company's Website -
TUSTIN, Calif., Feb. 7 /PRNewswire-FirstCall/ -- Peregrine Pharmaceuticals, Inc. (Nasdaq: PPHM), a clinical stage biopharmaceutical company developing monoclonal antibodies for the treatment of cancer and hepatitis C virus infection, today announced that senior management will present at the 10th Annual BIO CEO & Investor Conference on Tuesday, February 12, 2008 at 9:30 am EST. The conference will be held at the Waldorf-Astoria Hotel in New York City.
Paul J. Lytle, Peregrine's chief financial officer, will provide a review of recent corporate developments.
A live webcast and archived replay of the company's presentation will be available at the Investor Relations section of Peregrine's website at http://www.peregrineinc.com.
For more information about this conference, please visit: http://ceo.bio.org/opencms/ceo/2008/index.jsp
About Peregrine Pharmaceuticals
Peregrine Pharmaceuticals, Inc. is a biopharmaceutical company with a
portfolio of innovative product candidates in clinical trials for the
treatment of cancer and hepatitis C virus (HCV) infection. The company is
pursuing three separate clinical programs in cancer and HCV infection with
its lead product candidates bavituximab and Cotara(R). Peregrine also has
in-house manufacturing capabilities through its wholly owned subsidiary
Avid Bioservices, Inc. (http://www.avidbio.com), which provides development
and bio-manufacturing services for both Peregrine and outside customers.
Additional information about Peregrine can be found at
GendeLLindheim BioCom Partners
firstname.lastname@example.org Barbara Lindheim
(800) 987-8256 (212) 918-4650
|SOURCE Peregrine Pharmaceuticals, Inc.|
Copyright©2008 PR Newswire.
All rights reserved